Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Oklahoma Medical Research FoundationFounded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Founded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Publication Number
US-12352749-B2
Publication Date
2025-07-08
Expiration Date
Abstract
The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.
Core Innovation
The patent describes fully human monoclonal antibodies and antibody panels specific for Streptococcus pneumoniae capsular and cell-wall polysaccharides. Panels comprise two or more serotype-specific antibodies that bind S. pneumoniae or bind to antigens of S. pneumoniae and can be immobilized on solid supports such as beads, dipsticks, membranes, plates, or chips. Antibodies are defined by selected heavy and light chain variable domain amino acid sequences specified by SEQ ID NOS.
The document provides extensive variable region amino acid sequences for human monoclonal antibodies, functional binding profiles to numerous S. pneumoniae serotypes, frequency of cross-reactivity, and somatic hypermutation/clonality of ASC-derived antibodies. Kits comprise a panel immobilized on a solid support, a suitable container, and optionally an immunodetection reagent, with antibodies selected to bind serotypes 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 11B, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F, and CWPS.
The disclosure includes [procedural detail omitted for safety], recombinant expression and engineering formats (scFv, Fab, IgG, CDR grafting, isotype switching), purification, and experimental characterization for 137 antibodies with representative heavy and light chain variable sequences. Panels bind at least 15, optionally at least 18 or 21, pneumococcal serotypes and are suitable for incorporation into detection formats using immobilized antibodies on solid supports.
Claims Coverage
The claims include two independent claims and two main inventive features.
Panel of serotype-specific antibodies defined by specified variable domain sequences
A panel comprising two or more serotype-specific antibodies or binding fragments that bind Streptococcus pneumoniae or bind to antigens of S. pneumoniae immobilized on a solid support, with heavy chain variable domain polypeptides selected from SEQ ID NOS: 253 to 257, 269, 294 to 304, 331 to 337, 351 to 354, or 360 to 364, and light chain variable domain polypeptides selected from SEQ ID NOS: 286, 313 to 323, 344 to 350, 365 to 368, or 374 to 378; the panel is selected to bind serotypes 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 11B, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F, and CWPS.
Kit for detection of Streptococcus pneumoniae
A kit for the detection of Streptococcus pneumoniae comprising a panel of one or more serotype-specific antibodies or binding fragments immobilized on a solid support, a suitable container, and optionally an immunodetection reagent; the panel is selected to bind S. pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 11B, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F, and CWPS.
The independent claims cover panels of serotype-specific antibodies defined by specified heavy and light chain variable domain amino acid sequences and detection kits comprising such panels immobilized on a solid support with a suitable container and optional immunodetection reagent, with selection to bind a listed set of S. pneumoniae serotypes.
Stated Advantages
Not explicitly described in patent.
Documented Applications
A kit for the detection of Streptococcus pneumoniae comprising a panel of serotype-specific antibodies immobilized on a solid support, a suitable container, and optionally an immunodetection reagent.
Immunodetection reagents and assays, including labeled antibodies and detectable labels (radioactive, fluorescent, biological or enzymatic tags); detection formats recited include ELISA, competitive assays, immuno-PCR, and Western blot [procedural detail omitted for safety].
Therapeutic and theranostic uses including passive immunization, hyperimmune serum synergy with antibiotics, and antibody–antibiotic conjugates, as well as antibody conjugates to nanoparticles or liposomes.
Interested in licensing this patent?